Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03380351 · ClinicalTrials.gov registry record
Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC)
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 17
- Enrollment target
NCT03380351: Completed study, sponsored by Washington University School of Medicine.
NCT03380351 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03380351 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 17 participants
- Enrollment target
Study Summary
The goal of this study is to specify the interventions, implementation strategies and control conditions from the Sickle Cell Disease Implementation Consortium (SCDIC) using a mixed-methods approach to study site materials and conduct semi-structured qualitative interviews with site representatives (N=3 per site). We focused on the Emergency Department Working Group from the SCDIC working groups.
Primary Outcome
Detailed descriptions of the interventions being developed by the SCDIC including a) entity, or entities, targeted by the intervention; (b) functional domains targeted by the interventions; and (c) delivery system characteristics
Interventions
- BEHAVIORAL SCDIC interventions
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2024-03-30 |
What the finished NCT03380351 record still lists
NCT03380351 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SCDIC interventions is the first listed.
NCT03380351 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03380351 about?
NCT03380351 is a clinical study titled "Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC)". The goal of this study is to specify the interventions, implementation strategies and control conditions from the Sickle Cell Disease Implementation Consortium (SCDIC) using a mixed-methods approach to study site materials and conduct semi-structured qualitative interviews with site representatives ...
What is the current status of trial NCT03380351?
This trial is currently completed. The enrollment target is 17 participants. The study started on 2019-08-26. Estimated completion is 2024-03-30.
What interventions are being tested in trial NCT03380351?
The interventions under investigation include: SCDIC interventions (BEHAVIORAL).
Who is sponsoring clinical trial NCT03380351?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI